Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Emory University
With
National Cancer Institute (NCI)
Blue Earth Diagnostics
PRIMARY OBJECTIVE:
I. To determine if administering 20 mg furosemide intravenously (IV) at the time of radiotracer injection significantly reduces bladder activity compared with the same patient scanned without furosemide as internal control.
SECONDARY OBJECTIVES:
I. To compare detection rates of recurrent disease in blinded interpretations between the furosemide and non-furosemide 18FrhPSMA-7.3 PET/CT scans, with patients serving as their own internal controls.
II. To compare reader confidence in identifying prostate bed and other recurrent lesions on a 18F-rhPSMA-7.3 PET/CT with furosemide compared with 18F-rhPSMA-7.3 PET/CT without furosemide.
OUTLINE:
Patients receive 18F-rhPSMA 7.3 tracer IV and then undergo PET-CT scans with and without furosemide IV on study.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Adenocarcinoma of the prostate, post-prostatectomy
Biochemical recurrence of prostate cancer following radical prostatectomy (RP) with or without adjuvant or salvage therapy: PSA \>= 0.2 ng/mL followed by a subsequent confirmatory PSA value \>= 0.2 ng/mL
Age over 18
Ability to provide written informed consent
Patients with standard of care creatinine =\< 1.3 mg/dL performed within 90 days prior to enrollment
You may not be if
\- Inability to undergo 18F-rhPSMA PET-CT, contraindications to furosemide or urinary incontinence
